Home-based Transcranial Direct Current Stimulation (tDCS) for Major Depressive Disorders (MDD)

Not Applicable

Active, not recruiting

• Conditions: Major Depressive Disorder

• Registration Number: NCT05205915
• Lead Sponsor: Neuroelectrics Corporation

Brief Summary

This is an open label pilot feasibility telemedicine study. This pilot will involve a total of 37 at-home stimulation sessions (30-minutes each) of multichannel excitatory tDCS targeting the left dorsolateral prefrontal cortex (DLPFC) administered over 8 weeks, with a follow-up period of 4 weeks following the final stimulation session.

Detailed Description

This is an open label pilot feasibility telemedicine study. This pilot will involve a total of 37 at-home stimulation sessions (30-minutes each) of multichannel excitatory tDCS targeting the left dorsolateral prefrontal cortex (DLPFC) administered over 8 weeks, with a follow-up period of 4 weeks following the final stimulation session.

The main objective of the study is to assess the feasibility and safety of home-based tDCS for patients with MDD.

The treatment course will consist of an acute phase of 28 tDCS sessions, conducted daily (7 days per week) over 4 weeks.

Thereafter, participants will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:

1. Three tDCS sessions applied once every other day.

2. Three tDCS sessions applied once every third day.

3. Three tDCS sessions applied once every fourth day.

Study Timeline

• Study First Submitted: 2021-12-20
• Study First Submitted QC: 2022-01-12
• Study First Posted: 2022-01-25
• Study Start: 2022-02-02
• Status Verified: 2022-10
• Last Update Submitted: 2022-10-04
• Last Update Posted: 2022-10-05
• Primary Completion: 2022-12
• Study Completion: 2022-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

1. Major Depressive Disorder
2. Age >=18
3. Currently experiencing a major depressive episode of at least four weeks' duration
4. MADRS score at least 20 at trial entry.
5. Taking at least one approved antidepressant medication (except bupropion).
6. Has a healthcare provider, and a companion who can help administer study treatments; and be able to connect frequently with study staff
7. Access to wireless internet (wifi) connection

Exclusion Criteria

1. Any psychotic disorder.
2. Concurrent benzodiazepine medication.
3. High suicide risk
4. History of significant neurological disorder.
5. Skin lesions on the scalp at the proposed electrode sites.
6. Pregnancy.
7. Any antidepressant medications will be permitted (except bupropion) provided the medication dose has been unchanged for 4 weeks prior to trial entry.
8. Any cranial metal implants (excluding ≤1 mm thick epicranial titanium skull plates and dental fillings) or
9. Medical devices (i.e. cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant, vagus nerve stimulator);
10. Previous surgeries opening the skull leaving skull defects capable of allowing the insertion of a cylinder with a radius greater or equal to 5 mm.
11. Substance use disorder (including alcohol) within the past year.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Percentage of incomplete and missed sessions (%)	From baseline to 4-week follow up across study subjects	Feasibility will be evaluated using home-based data as recorded in the Neuroelectrics portal. Range \[0,100\]. Higher is worse
Incidence of Serious Adverse Events (SAE)	From baseline to 4-week follow up across study subjects	Safety will be assessed by number and type of side effects
Median percentage change in Montgomery-Asberg Depression Mood Rating Scale (MADRS) scores	From baseline to 4-week follow up across study subjects	The primary efficacy measure for this study will be the median percent change from baseline to the end of the 4-week post-treatment follow-up period in the observer-rated Montgomery-Asberg Depression Mood Rating Scale (MADRS) (Montgomery and Asberg, 1979). Range \[0,100\]. Higher is worse

Secondary Outcome Measures

Name	Time	Method
Change in the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) score	Change from baseline to 4-week follow-up in the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF)	Range \[14,70\]. Higher is better
Change in the Quick Inventory of Depressive Symptomatology (QIDS-SR) score	Change from baseline to 4-week follow-up in the participant-rated Quick Inventory of Depressive Symptomatology (QIDS-SR)	Range \[0,27\]. Higher is worse
Response rate	From baseline to the 4-week follow-up	Response rate is the secondary efficacy endpoint and will be calculated for the study subjects, where clinical response is defined as ≥ 50% improvement in Montgomery-Asberg Depression Mood Rating Scale (MADRS) score. Higher is better
Median percentage change in Montgomery-Asberg Depression Mood Rating Scale (MADRS) scores	From baseline to the end of week 4 of treatment, and to the end of week 8 of treatment.

Trial Locations

Locations (4)

Healthcare Innovations Institute, LLC; 🇺🇸 Coral Springs, Florida, United States

Oceane7 Medical & Research Center, Inc.; 🇺🇸 Miami, Florida, United States

Renew Health Clinical Research, LLC; 🇺🇸 Snellville, Georgia, United States

Conrad Clinical Research; 🇺🇸 Edmond, Oklahoma, United States